Hutchison China MediTech Limited announced that it has initiated a Phase II study of sulfatinib in second-line biliary tract cancer (BTC) patients in China. Sulfatinib is an oral, novel angio-immunokinase inhibitor that selectively targets vascular endothelial growth factor receptor ("VEGFR"), fibroblast growth factor receptor ("FGFR") and colony-stimulating factor-1 receptor (CSF-1R), three key tyrosine kinase receptors involved in tumor angiogenesis and immune evasion. The first drug dose was administered on January 9, 2017. This Phase II study is a multi-center, single-arm, open-label study to evaluate the efficacy and safety of sulfatinib as a monotherapy in treating advanced or metastatic BTC patients who failed one prior systemic therapy. The primary endpoint is progression free survival ("PFS") at 16 weeks, with secondary endpoints including objective response rate ("ORR"), disease control rate ("DCR"), duration of response, PFS, overall survival ("OS") and safety.